Neurocrine Biosciences, Inc. Share Price

Equities

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 23/05/2024 am IST 5-day change 1st Jan Change
139.4 USD -0.80% Intraday chart for Neurocrine Biosciences, Inc. -1.81% +5.82%
Sales 2024 * 2.22B 185B Sales 2025 * 2.54B 212B Capitalization 14.03B 1,169B
Net income 2024 * 430M 35.81B Net income 2025 * 661M 55.05B EV / Sales 2024 * 5.42 x
Net cash position 2024 * 2B 166B Net cash position 2025 * 2.79B 233B EV / Sales 2025 * 4.42 x
P/E ratio 2024 *
34 x
P/E ratio 2025 *
22.1 x
Employees 1,448
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.2%
More Fundamentals * Assessed data
Dynamic Chart
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing MT
Transcript : Neurocrine Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM
Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 CI
Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 CI
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults CI
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 CI
Neurocrine Biosciences Presents CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024 CI
UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating MT
Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell MT
Transcript : Neurocrine Biosciences, Inc., Q1 2024 Earnings Call, May 01, 2024
Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q1 Revenue $515.3M, vs. Street Est of $512M MT
Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Reports Q1 EPS $1.20, vs. Street Est of $1.29 MT
Neurocrine Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
More news
1 day-0.80%
1 week-1.81%
Current month+1.37%
1 month+4.32%
3 months+4.54%
6 months+25.64%
Current year+5.82%
More quotes
1 week
137.76
Extreme 137.76
145.78
1 month
134.79
Extreme 134.79
145.78
Current year
128.00
Extreme 128
148.37
1 year
89.04
Extreme 89.04
148.37
3 years
71.88
Extreme 71.875
148.37
5 years
71.88
Extreme 71.875
148.37
10 years
12.63
Extreme 12.6325
148.37
More quotes
Managers TitleAgeSince
Founder 66 01/92/01
Director of Finance/CFO 44 01/17/01
Chief Tech/Sci/R&D Officer 60 30/21/30
Members of the board TitleAgeSince
Director/Board Member 75 01/99/01
Director/Board Member 72 01/15/01
Founder 66 01/92/01
More insiders
Date Price Change Volume
22/24/22 139.4 -0.80% 1,173,772
21/24/21 140.6 -0.78% 538,947
20/24/20 141.6 -0.45% 500,626
17/24/17 142.3 +0.27% 641,937
16/24/16 141.9 -0.06% 670,978

Delayed Quote Nasdaq, May 23, 2024 at 01:30 am IST

More quotes
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
139.4 USD
Average target price
158.4 USD
Spread / Average Target
+13.63%
Consensus